Glenn Rockman

Glenn is a finance professional with 20 years of experience in venture capital and investment banking.

Prior to founding Adjuvant Capital in 2018, Glenn was a Managing Partner at the investment advisory firm responsible for managing Global Health Investment Fund (GHIF).  Prior to GHIF, Glenn was an Executive Director in J.P. Morgan’s Social Finance unit, where he helped the firm’s non-profit clients maximize the financial resources available to advance their missions. He served in similar capacities at J.P. Morgan for more than a decade before leaving to focus exclusively on life sciences investing.

At Adjuvant, Glenn oversees the firm’s investments in VitriVax (board member), Univercells (board member), Themis (acquired by Merck in 2020), X-Vax (board member), InDevR, and Codagenix (board member). At GHIF, he oversaw the fund’s investments as a board member at IanTech (sold to Carl Zeiss Meditec), EuBiologics (KOSDAQ: 206650), and Moxidectin for Onchocerciasis Limited (PRV asset sold to Novo Nordisk).

Outside of life sciences investing, Glenn is actively engaged with the Research Investment for Global Health Technology Foundation (RIGHT Foundation) as a board member. He is also Vice Chair of WaterEquity, an asset management company focused on water and sanitation investments in emerging markets.

Glenn earned an AB in public policy from the Princeton School of Public and International Affairs.